areas with metaplasia. In addition, prostate of PvþHg-De animals suffered loss of epithelial conformation and alveolar limitation in relation to stroma. Angiogenesis and infiltration of immune system cells were observed throughout the prostate tissue. However, nerve transection did not significantly affect the expression of the measured receptors.
INTRODUCTION AND OBJECTIVES:
Metastasis is a complex cascade that involves both intravasation of tumor cells into systemic circulation and extravasation into the target metastatic site. Although visualizing tumor cell motility in vivo has been established, the underlying mechanisms of tumor cell metastasis remain largely unknown. In this study, we developed an in vitro model for recapitulating an in vivo microenvironment to observe prostate carcinoma cell metastasis.
METHODS: To allow for high resolution and real-time imaging of tumor intravasation, we developed a micro-metastatic model by constructing a microfluidic polydimethylsiloxane (PDMS) device to mimic a primary tumor site and a metastatic site with an interconnecting vascular-type loop in three-dimensions. We also developed a macromodel device for creating a primary tumor site and metastatic sites. The primary tumor and metastatic sites were connected with vessel-mimicking tubing which was coated with type I collagen. Cell culture media was circulated between the primary and metastatic sites using a peristaltic pump. Prostate carcinoma cells (PC3/luc) were labeled with Cell Trackerâ and seeded into primary tumor site containing biomimetic collagen extracellular matrix within a microfluidic device or 6-well tissue culture plate. Bone stromal cells (HS-5) were seeded into metastatic microenvironment site.
RESULTS: We observed in both devices intravasation and circulation of the tumor cells using fluorescent microscope and plate reader. In addition, we found tumor cells at the metastatic site in the macromodel.
CONCLUSIONS: In summary, we have developed several model systems that mimic key steps of the metastatic cascade including intravasation and the accompanying presence of circulating tumor cells, followed by extravasation and the accompanying presence of disseminated tumor cells. Such systems will allow both exploration of mechanisms of metastasis and development of novel biologic assays for discovery of new therapeutics. METHODS: Cell-uptake selection: Incubating prostate normal cells in the 2'-OMe-RNA pools (counter-selection), washing and collecting the unbound RNAs and presenting them to PCa cells for cellspecific binding and uptaking. Extracting the RNAs which bind to PCa cells (cell-uptake selection) and amplifying them via rtPCR. The rtPCR products were then transcribed into 2'-OMe-RNAs for the next round of selection and sequenced for Apt indentification in the last round selection. Encapsulating docetaxel (Dtxl) in Apt-targeted NPs (PLGA-PEG-Apt-Dtxl) via single emulsion method. The drug loading efficacy and payload releasing profile of the NPs were analysised in vitro. PC3 cells were planted subcutaneously on SCID mice to establish the prostate cancer model. PLGA-PEG-Apt-Dtxl were applied to the SCID mouse to evaluate the therapy efficiency of the Apt-targeted NPs.
RESULTS: Three Apts were isolated through cell-uptake selection: XEO2 and XEO9 can specificly bind to PC3 cells, and XEO6 can specificly bind to LNCaP cells. XEO2 was further trunked and modified into XEO2 mini, which with a smaller size (32 bp) and keep the targeting properties. The size of PLGA-PEG-Apt NPs was around 180 nm and the zeta potential is around -20 mV. The Dtxl loading efficacy of PLGA-PEG nanoparticles was 14.76% and the drug loading efficiency can be up to 73.8%. In vitro and in vivo experiments demonstrated that XEO2 mini targeted NPs can specificly bind to PC3 cells and better therapy efficiency was observed in SCID mice PCa models in compare with non targeted NPs or Dtxl only (Figure 1) .
CONCLUSIONS: A group of Apts which can specifically target to PCa cells have been generated by a simple cell-uptake selection progress. Cell-uptake selection can be done without prior knowledge of target molecules and can be applied in a wide variety of onlogic diseases. A PLGA-PEG-Apt-Dtxl targeted NP platform has been developed and demonstrated enhanced therapeutic efficacy in prostate cancer. METHODS: 5x10 5 VCaP-, LuCaP136-and LuCaP147 cells were injected into the prostate of male CB17-SCID mice (n¼8 for each cell line). During 12 weeks of follow-up, orthotopic tumor growth and the development of metastases was monitored by repetitive serum-PSA measurements and imaging studies (ultrasonography, CT, MRI). At autopsy, primary tumors and metastases were harvested and examined by conventional histology (H&E) and immunohistochemistry (CK5, CK8, AMACR, AR, Ki67, ERG, PSA). From the results of the imaging studies and PSA-measurements, tumor volume doubling time, tumor-specific growth rate and PSAdensity were calculated for each cell line.
RESULTS: All 24 mice developed orthotopic tumors, whose growth could be reliably monitored by ultrasonography, CT, MRI and serum-PSA measurements. 4 animals died during follow-up (1 in the VCaP group, 1 in the LuCaP136 group, 2 in the LuCaP147 group). Mean PSA-density was 433.9 ng/ml per ml tumor in the VCaP group, 6.5 ng/ml per ml tumor in the LuCaP136 group and 11.2 ng/ml per ml tumor in the LuCaP147 group. Tumor-specific growth rate and tumor volume doubling time were 3.87% per day and 21.24 days in the VCaP group, 3.11% and 27.57 days in the LuCaP!36 group and 4.47% and 16.2 days in the LuCaP147 group, respectively. In up to 100% of animals, lymph node metastases could be detected after 12 weeks (5/7 in the VCaP group, 6/7 in the LuCaP136 group, 6/6 in the LuCaP147 group). These could also be visualized by ultrasonography and MRI. The results of immunohistochemistry are depicted in table 2. Immunohistochemistry showed positive CK8, AR and AMACR as well as negative CK5 reactions in all tumors. ERGstaining was positive in VCaP, and negative in both LuCaP tumors, Ki67 proliferation indices were >90% in all groups.
CONCLUSIONS: By using different monolayer as well as 3D spheroid cell cultures in an orthotopic xenograft model, we could establish an innovative, versatile in-vivo model of prostate cancer, which enables the study of both intraprostatic tumor growth as well as metastatic spread to regional lymph nodes.
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MP70-09 IDENTIFICATION OF NINE NEW SUSCEPTIBILITY LOCI FOR PROSTATE CANCER IN THE JAPANESE POPULATION
Ryo Takata*, Morioka, Japan; Shusuke Akamatsu, Kyoto, Japan; Hidewaki Nakagawa, Tokyo, Japan; Naoki Terada, Kyoto, Japan; Yoichiro Kato, Mitsugu Kanehira, Jun Sugimura, So Omori, Takaya Abe, Morioka, Japan; Johji Inazawa, Tokyo, Japan; Osamu Ogawa, Kyoto, Japan; Wataru Obara, Morioka, Japan INTRODUCTION AND OBJECTIVES: Prostate cancer (PC) is one of the most common malignancies in males throughout the world. Although the mechanisms by which prostate cancer develops and progresses are not clear, there is considerable evidence that genetic factors are important in its etiology. Recent genome-wide association studies (GWAS) have identified common variants at multiple loci that have moderate effects on PC risk. However, GWAS for prostate cancer have been undertaken exclusively among European populations. Further GWAS of Asian and other ethnic populations are required to identify additional susceptibility loci for PC and to enhance the understanding of the complex genetic effect on prostate carcinogenesis. To identify genetic factors that confer risk of PC in the Japanese population, we carried out extensive GWAS using Japanese case and controls.
METHODS: We carried out a genome-wide association study of 511,810 SNPs using 5,088 Japanese men with PC and 10,682 healthy control subjects. We obtained 7,521,072 SNPs information by imputation using 1000 Genomes Project data. In addition, we conducted replication study in an independent set of 4,818 Japanese PC patients and 73,261 control subjects.
RESULTS: From the 108 associated SNPs reported in previous GWAS, we confirmed the association of 49 SNPs at P < 0.05 in the Japanese population. The remaining 59 SNPs showed no association (P > 0.05). Therefore, it became evident that the SNPs associated with PC pathogenesis greatly varies depending on race. In addition, we performed replication study for 101 SNPs which indicated P < 1.0 x 10 -5 in the GWAS. As a result, we identified nine new loci for PC susceptibility at 1p36, 8q24, 10q22, 12p13, 12q21, 15q22, 20p13 and 22q13 (P ¼ 3.34 x 10 -8 -5.28 x 10 -20 ). Moreover, the polymorphisms of SNP and the expression of the surrounding gene showed a significant correlation with QTL analysis in the 2 associated SNPs.
CONCLUSIONS: This study had an advantage of eliminating of affect for genetic heterogeneity, since we conducted GWAS using genetically quite a homogeneous population of Japanese. These findings advance our understanding of the genetic basis of prostate carcinogenesis and highlight the genetic heterogeneity of PC susceptibility among different ethnic populations.
